GlassScriptPhysician profile
Daniel Desrivieres
NPI 1619041506
$6,446.75
in general payments reported to CMS, 2019-2025
23 companies · $857 in 2025
The $857 reported for 2025 was more than what 89% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,549 · 2020: $292 · 2021: $1,248 · 2022: $778 · 2023: $941 · 2024: $781 · 2025: $857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,579.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,579.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $1,153.43 | 2019-2021 | |
| Sight Sciences, INC. | $1,121.02 | 2019-2023 | Omni Surgical System |
| Bausch & Lomb Americas INC. | $725.64 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Abbvie INC. | $690.40 | 2022-2025 | Durysta, Lumigan, Alphagan P |
| Synergeyes, INC. | $520.76 | 2019 | |
| Dompe US, INC. | $411.67 | 2023-2025 | Oxervate |
| Aerie Pharmaceuticals, INC. | $289.19 | 2020-2021 | |
| Glaukos Corporation | $259.91 | 2019-2025 | |
| Eyevance Pharmaceuticals LLC | $149.83 | 2022 | |
| Biotissue Holdings INC. | $128.35 | 2023-2024 | |
| Sun Pharmaceutical Industries INC. | $105.89 | 2024 | |
| Mallinckrodt Hospital Products INC. | $105.87 | 2025 | Acthar |
| Oyster Point Pharma, INC. | $105.40 | 2022 | |
| Visioneering Technologies, INC. | $104.44 | 2019 | |
| Genzyme Corporation | $102.77 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $97.85 | 2025 | Xdemvy |
| Alcon Vision LLC | $78.59 | 2019 | |
| Lkc Technologies, INC. | $58.53 | 2024 | |
| Amgen INC. | $51.67 | 2024 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $50.23 | 2020-2021 | |
| Samsara Vision | $50.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $48.89 | 2019-2022 | |
| Optos, INC. | $36.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Desrivieres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.